anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Child undernutrition persists in Cambodia despite recent progress. As Cambodia undergoes a shift in dietary consumption that coincides with economic, demographic, and epidemiologic changes, there is risk of ultra-processed foods and sugar-sweetened beverages displacing nutrient-dense foods during the critical period of infant growth in the first 24 months. The aim of this study was to assess the introduction and intake of foods of low nutritional value and sugar-sweetened beverages and their association with undernutrition among children 24 months of age in rural and semi-urban Cambodia. Cross-sectional analyses of a 24-h dietary recall from a sample (n = 377) of 24-month-olds found that the majority of infants had been introduced to packaged salty snacks and sweets by 12 months of age and to sugar-sweetened beverages by 15 months. By 24 months of age, 78% of children had consumed foods of low nutritional value and 57% consumed a sugar-sweetened beverage on the previous day. Multivariate logistic regression analyses demonstrated that infant intake of a flavored sugary drink on the previous day was associated with over two times the odds of both stunting and wasting, and consumption of packaged sweets on the previous day was associated with over two times the odds of wasting, but no association was found with stunting. These findings underscore the need to improve educational and policy interventions to support healthy feeding practices for infants and young children.
PROBLEM TO BE SOLVED: To obtain a wrinkles improver containing a guanidine derivative having a specific structure or its acid addition salt as an active ingredient, capable of suppressing occurrence of wrinkles without impairing normal skin physiology and excellent in effect for eliminating wrinkles and having good feeling to users. SOLUTION: This wrinkles improver is obtained by using a guanidine derivative of formula I [A and B are each a 2-8C alkylene; D is a direct bond or a 1-6C alkylene; E is H, an alkyl, an aralkyl or an aryl; (m) is 1-6; (n) is 0-6; R<1> is H, an alkyl or (AO)m (BO)n -D-E] or formula II [(k) is 1-10; G is H, OH, COOH, sulfonic acid or phosphoric acid] or its acid addition salt. The wrinkles improver is useful as a cosmetic for preventing aging. The content of the active ingredient is preferably 0.001-50wt.%. An organic acid or its ester in an amount of 0.001-30wt.% is preferably further added to the system. A dicarboxylic acid is preferably used as the organic acid. The compound of formula I is obtained by reacting, e.g. a compound of formula III with a guanidination reagent.
The invention discloses a humanized antibody specifically binding to human plasma membrane vesicle associated protein PV-1 and application thereof. Specifically disclosed are humanized antibodies having the amino acid sequence of SEQ ID Nos. 16, 18, 20, 22 or 24 for the light chain variable region and SEQ ID Nos. 15, 17, 19, 21 or 23 for the heavy chain variable region. According to the invention, the humanized antibody is obtained by performing bioinformatics analysis, PTMs risk assessment, 3D homologous modeling, germline selection, CDR grafting, back mutation and modification on the structure and sequence information of the murine monoclonal antibody. The humanized antibody has weak non-characteristic adsorption capacity, strong colloid stability, higher humanized degree, difficult initiation of immunogenic reaction and high affinity, can be prepared into an antibody medicament for clinically treating PV-1 overexpression related diseases, and has very wide prospect and important biomedical significance in the fields of medicament application and the like.
Ischemic compression was gradually applied pressure to the trigger point with your thumb. The patient will likely feel referred pain in a question mark pattern (along the back of the neck, around the side of the head, and then a focused pain right behind the eye). Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points will be treated. Then apply a few effleurage strokes to flush out the area and follow up with a passive stretch to the muscle.
Patients taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 2.5 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
The invention discloses a synthetic polypeptide, a synthetic method and application thereof, and a gene for coding the synthetic polypeptide. The amino acid sequence of the polypeptide is: Leu-Val-Tyr-Pro is shown in a sequence table SEQ ID No. 1. The polypeptide of the invention is synthesized by a solid phase synthesis method by using a polypeptide synthesizer. The polypeptide of the invention passes an oxygen radical absorption capacity experiment (ORAC), and the result shows that the polypeptide has certain antioxidant capacity. The polypeptide is applied to an ethanol-induced liver injury cell model, and an MTT detection method is used for detecting the protection effect of the polypeptide on LO2 cells, so that the result shows that the polypeptide can inhibit the survival rate reduction of the ethanol-induced LO2 cells, has a certain liver protection effect, and can be applied to the protection of alcoholic liver diseases.
PCT No. PCT/GB93/02267 Sec. 371 Date Jul. 5, 1995 Sec. 102(e) Date Jul. 5, 1995 PCT Filed Nov. 4, 1993 PCT Pub. No. WO94/10323 PCT Pub. Date May 11, 1994An adenovirus or adenovirus-like particle which has a modified binding specificity conferred by a binding moiety. The binding moiety is heterologous to the adenovirus and is incorporated as a fusion protein with the fiber protein. This allows the adenovirus or adenovirus-like particle to bind to a target cell which is not the natural host cell of the virus. The penton fiber is modified by the insertion or, deletion, or substitution of amino acid residues, that disrupt the host-cell binding function so that the adenovirus or adenovirous like particle does not bind the natural host cell.
A cleansing-agent especially suited for motorists' personal use is composed of a paste or solution of polyvinyl alcohol and an aromatic or cosmetic substance; when applied to the hands or other surface and rubbed it forms crumbs which lift the dirt.  A suitable strength of the polyvinyl alcohol solution is 2--10 per cent.  There may also be present: fat-dissolving substances such as organic solvents or higher fatty acids; starchy bodies such as maize starch or potato starch; and the juices of plants such as carragheen moss.  Cosmetics specified are powder, tinting agents, alcohol, and glycerine.  The prior use of milk of rubber is referred to.  The Specification as open to inspection under Sect. 91 describes also the use of a paste or solution of polyvinyl alcohol alone. This subject-matter does not appear in the Specification as accepted.
Sessions 1 and 2 involved information-gathering, discussion of the ACT model of OCD and ERP, and introduction to self-monitoring of rituals. Session 3 involved the development of an exposure hierarchy and response prevention plan, and further explanation of the ACT-based approach to ERP which focuses on learning flexible responding in the presence of obsessions, anxiety, and urges to ritualize. Exposure practices (sessions 4-16) were procedurally similar to the ERP condition, but focused on the facilitation of ACT processes rather than on fear extinction. Homework exposure practice was linked to the participant's goals and values. Session 16 included an ACT model of relapse prevention focusing on following one's values in the presence of obsessive thoughts and compulsive urges.
FIELD: medicine. SUBSTANCE: vaccine contains cholerogenous anatoxin and O- antigen from Inab V. Cholrae 569B strain and immunogenic antigen complex. The immunogenic antigen complex is obtained from culturing liquid medium of V. cholerae strain O139 serovar. It consists of the basic somatic O- antigen of lipopolysaccharide nature of O139 serovar with molecular mass of 1000 kD, glycoprotein capsule of O139 serovar with molecular mass of 600 kD and protein exoenzymes of O139 serovar with molecular mass of 100-200 kD. It contains neuraminidase, phospholipase, lipase, and protease as exoenzymes. When required, the vaccine contains filler for making tablets and capsules (starch, sugar, calcium stearate or talc). EFFECT: enhanced effectiveness in protection against cholera vibrio strain O139. 1 dwg, 3 tbl
The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a sample of a subject, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in the subject with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. The present invention discloses various diseases that have up-regulated or down-regulated PARP and can be treated with PARP inhibitors or PARP activators, respectively. The examples of the diseases include cancer, inflammation, metabolic disease, CVS disease, CNS disease, disorder of hematolymphoid system, disorder of endocrine and neuroendocrine, disorder of urinary tract, disorder of respiratory system, disorder of female reproductive system, and disorder of male reproductive system.
This group includes 34 patients who axillary web syndrome will receive Manual lymphatic drainage massage with traditional physical therapy exercise program (strength, core stability, flexibility, muscle control, posture and breathing). Patients will receive 3 sessions per week for 9 weeks; time of session is 30 minutes.
Corneal collagen cross linking showed effective results in stabilizing progressive keratoconic corneas. It is the only treatment that halts progression of keratoconus, It was first described in 1998 by Spoerl et al . A major limitation of the procedure that it cannot be used in corneas with pachymetry less than400 micrometers based on the fact that an irradiance of 0.37 mW/cm2 has been found to be cytotoxic for the endothelial cell layer. Since the absorption coefficient for the human corneas is 70 cm-1 and the intended surface irradiance is 3.0 mW/cm2, the 0.37 mW/cm2 irradiance is reached at 300 microns depth. In a 400 microns thick cornea saturated with riboflavin, the irradiance at the endothelial level is 0.18 mW/cm2, which is a factor of 2 smaller than the damage threshold. Therefore, the 400 microns limit is considered to be a safe limit to protect the endothelium and intraocular structures from the hazards of UV irradiation 12 However , the patients with advanced ectasia who are desperately in need for cxl , are the same ones who have thin corneas often below the threshold which is considered to be safe for CXL treatment However further studies with longer follow up and larger numbers of cases are needed to confirm our findings.
PROBLEM TO BE SOLVED: To obtain a sheet-like pack cosmetic enabling to easily judge a proper peeling time and useful as a cosmetic for removing pore fats, etc., by including a porous base cloth and a cosmetic comprising a specific amount of menthol, water, etc. SOLUTION: This sheet-like cosmetic comprises (A) a cosmetic comprising (i) 0.01-0.3 wt.% of menthol such as 1-menthol or camphor such as dl-camphor, (iii) 0.1-75 wt.% of a coating film-forming agent such as polyvinyl alcohol having an average mol.wt. of 100,000 to 1,000,000 and (iii) <=27 wt.% of water, and (B) a porous base cloth such as a nonwoven fabric comprising polypropylene/ rayon fibers and having a porosity of 70-99% and a thickness of 30-1500 μm. The sheet like cosmetic is obtained e.g. by coating the component A controlled to a water content of 10-95 wt.% on a releasing sheet such as a polypropylene sheet, superposing the component B on the coated component A to impregnate the component A into the component B, and subsequently drying the product.  The objective cosmetic is, preferably used by supplying water to a skin site to be stuck and subsequently sticking the cosmetic to the skin site.
This study was the second year.The purpose of this study is to evaluate the effectiveness of the lifestyle modification intervention for overweight employees with obstructive sleep apnea. A randomized control trial with single blind will be used. Stratified with proportional randomized sampling will be employed and 160 suitable participants will be recruited from 4 electronics industries in northern of Taiwan. The subjects will be randomly divided into three groups. The total duration of intervention program is 6 months. Only the intervention group received the Combining Smartphone Application with lifestyle modification Intervention. The home portable sleep monitor will be used to collect the change of AHI at baseline, 3, and 6 months after intervention.
A HCV particle formation promoter is capable of promoting formation of HCV particles in culture cells, and a method enhances production of HCV particles. A method evaluates an anti-HCV agent candidate substance, and a method produces a HCV vaccine. The HCV particle formation promoter includes as an active ingredient a statin or a pharmaceutically acceptable salt thereof. Addition of the statin or pharmaceutically acceptable salt thereof to HCV-infected culture cells can promote formation of infectious HCV particles and enhance production of the particles. In addition, an anti-HCV agent candidate substance is evaluated by culturing HCV-infected cells in the presence of the HCV particle formation promoter and the anti-HCV agent candidate substance. Further, a HCV vaccine is produced by using HCV particles produced by the method of enhancing production of HCV particles.
AndroGel 1.62% was applied topically once daily in the morning beginning at the Day 1 Visit after confirmed valid ambulatory blood pressure monitoring (ABPM) assessment and was applied at approximately the same time each day after that during the study, for approximately 16 weeks. The starting dose of AndroGel 1.62% was 40.5 mg of T (2 pump actuations, applied to the upper arms and shoulders) and was titrated up or down by 20.25 mg or remained the same as assessed by morning serum T levels at Weeks 2 and 4.
PURPOSE: A pharmaceutical composition containing benzylisothiocyanate is provided to suppress differentiation into adipocytes and to prevent and treat obesity and lipid-associated metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-associated metabolic diseases contains benzyl isothiocyanate as an active ingredient. The metabolic diseases are diabetes, hyperlipidemia, fatty liver, artheriosclerosis, hypertension, cardiovascular diseases or combination thereof. The pharmaceutical composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, external use, suppository, or sterilized injection solution. A health food for preventing and treating obesity and lipid-associated metabolic diseases contains benzylisothiocyanate as an active ingredient. The health food is a capsule, tablet, granule, powder, or drink.
The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with Press Needles treatment will be treated with 2-week needle retention, 20-second pressing 3 times a day and needle replacement performed every 5 days. The needles are inserted 0.9 mm deep at the acupuncture points HT7 Shenmen, PC6 Neiguan, ST36 Zusanli and SP6 Sanyinjiao.
The invention concretely relates to a formula and a preparation method of a Hui Nationality traditional Chinese medicinal Rhizoma Curcumae and Araiia chinensis L. root bark esophagus cancer treatment granule. The granule is a green high-tech Chinese herbal medicine used for treating the esophagus cancer. The granule is a traditional Chinese medicinal granule prepared through the following steps: mixing of Rhizoma Curcumae, Araiia chinensis L. root bark, Smilax scobinicaulis C.H. Wright, Salvia miltiorrhiza and other Chinese herbal medicines according to a certain ratio, water adding, decoction, extraction, concentration and granulation. The granule is mainly used for treating the esophagus cancer, and also is used for treating throat cancer, stomach cancer, colorectal cancer and other digestive system cancers. The granule has the characteristics of suitable medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers. The granule fundamentally improves the body functions and prevents and treats cancer cancerization at a low cost in order to recover the health of bodies.
Participants in this arm will not receive any notifications for the entire duration of the trial. Primary and secondary outcomes will still be collected on participants in arm 2 through the study app and Fitbit.
Genomic instability arising from defective responses to DNA damage1 or mitotic chromosomal imbalances2 can lead to the sequestration of DNA in aberrant extranuclear structures called micronuclei (MN). Although MN are a hallmark of ageing and diseases associated with genomic instability, the catalogue of genetic players that regulate the generation of MN remains to be determined. Here we analyse 997 mouse mutant lines, revealing 145 genes whose loss significantly increases (n = 71) or decreases (n = 74) MN formation, including many genes whose orthologues are linked to human disease. We found that mice null for Dscc1, which showed the most significant increase in MN, also displayed a range of phenotypes characteristic of patients with cohesinopathy disorders. After validating the DSCC1-associated MN instability phenotype in human cells, we used genome-wide CRISPR-Cas9 screening to define synthetic lethal and synthetic rescue interactors. We found that the loss of SIRT1 can rescue phenotypes associated with DSCC1 loss in a manner paralleling restoration of protein acetylation of SMC3. Our study reveals factors involved in maintaining genomic stability and shows how this information can be used to identify mechanisms that are relevant to human disease biology1.
Daily VR only. Daily VR use every 3 hours up to 30 minutes at a time.
Participants undergo photoacoustic imaging of the breast over 30 minutes. At subject's discretion, imaging may repeat for a total of 10 studies, each in a separate day.
The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine, α-hydrazinohistidine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
The research purpose of this project is to observe the effectiveness and safety of Wulingsan single decoction granules compared with traditional powder, co-decoction granules and analogues in the treatment of metabolic syndrome in combination with conventional therapies. ; Compared with Wulingsan traditional powder and co-decoction granule group, observe the effectiveness and safety of traditional powder combined with conventional therapy in the treatment of metabolic syndrome. The trial adopts a randomized, partially double-blind, controlled, multi-center clinical research method. A total of 320 cases were included in 4 groups, namely, single decoction group, co-decoction group, powder group, and simulated agent group. The four groups of patients all received basic health education, diet control and increased exercise guidance. All the patients in the group have taken western medicine according to their own conditions and followed the doctor's instructions for hypoglycemic, blood pressure, and lipid-lowering treatments. After joining the group, they continue to take the medicine at the original dose, and the patients are advised not to change the medicine during the observation period. Take 12 weeks as a course of treatment, and the observation period is set to 12 weeks. Follow up every 4 weeks.
This is a single arm phase of the study. Every subject will receive the experimental treatment (MAG-EPA) at 1,5g/day for a period of eight weeks.
The Ex-PRESS is a miniature stainless steel glaucoma device, developed as an alternative to trabeculectomy mainly for patients with primary open-angle glaucoma.It has been proved to be as effective as trabeculectomy in a series of researches. However the early postoperative complication of Ex-PRESS implantation is less frequent compared with trabeculectomy. Ex-PRESS was designed initially for open angle glaucoma, gradually some scholars used it in refractory postpenetrating keratoplasty glaucoma and in vitrectomized glaucoma,which showed that Ex-PRESS shunt implantation was an effective procedure too. We analyzed the clinical efficacy and safety of combined phacoemulsification and Ex-PRESS implantation for PACG patients with cataract. Data was recorded before surgery and postoperatively at 1 week and 1, 3, 6, 12,18,24,30,36 months，which included intraocular pressure (IOP), best corrected visual acuity (BCVA), number of medications, complications, corneal endothelial cell density and anterior segment optical coherence tomography(AS-OCT). Efficacy was assessed by IOP values and success rates. Complete success was determined by IOP between 5 and 21mmHg without medications.
Risk Summary

There are no available data on the effects of BEVESPI AEROSPHERE, glycopyrrolate, or formoterol fumarate on the breastfed child or on milk production. There are no available data on the presence of glycopyrrolate or formoterol fumarate in human milk. Formoterol fumarate and glycopyrrolate have been detected in the plasma of undosed rat pups suckling from exposed dams [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEVESPI AEROSPHERE and any potential adverse effects on the breast-fed child from BEVESPI AEROSPHERE or from the underlying maternal condition.

Animal Data

In the reproductive/developmental toxicity study in rats, plasma levels of glycopyrrolate were measured in pups on post-natal day 4. The maximum concentration in the pups was 6% of the maternal dose of 10 mg/kg/day (pup plasma concentration of 96 ng/mL at 1 hour after dosing corresponded with 1610 ng/mL in the dam at 0.5 hours after dosing).

In the fertility and reproduction study in rats, plasma levels of formoterol were measured in pups on post-natal day 15 [see Use in Specific Populations (8.1)]. It was estimated that the maximum plasma concentration that the pups received from the maternal animal, at the highest dose of 15 mg/kg, after nursing was 4.4% (0.24 nmol/L for a litter vs. 5.5 nmol/L for the mother).